NCI, Foundation Medicine, and Five Pharma Firms Kick off Lung-MAP Trial | GenomeWeb

NEW YORK (GenomeWeb) — A group of pharmaceutical companies, research groups, foundations, and the clinical sequencing firm Foundation Medicine have joined to initiate a multi-drug, multi-arm, biomarker-driven clinical trial for patients with squamous cell carcinoma called the Lung Cancer Master Protocol, or Lung-MAP.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.